Polycystic ovary syndrome affects up to 18 percent of women of reproductive age. This condition is a leading cause of anovulatory infertility, which accounts for roughly 30 percent of all female infertility cases. Treatment outcomes vary, with about 36 percent achieving ovulation within three cycles of clomiphene citrate.
Key Takeaways
- 15–18% prevalence of PCOS among reproductive-age women, defined by commonly used criteria
- 5.0–8.0% prevalence of PCOS among women of reproductive age in the general population (meta-analytic estimates)
- PCOS affects approximately 6–13% of women worldwide of reproductive age (range across studies/criteria)
- PCOS increases the likelihood of irregular menstrual cycles; this contributes to delayed conception and infertility presentation
- PCOS is a risk factor for ovarian hyperstimulation syndrome (OHSS) especially when using gonadotropins; modern antagonist protocols reduce OHSS risk
- In OHSS prevention studies, the use of GnRH antagonists reduces the incidence of severe OHSS compared with GnRH agonist long protocols (reported relative reduction in randomized evidence)
- Up to 20% of women with PCOS have difficulties conceiving despite ovulation induction (study-dependent)
- In PCOS, clomiphene citrate results in pregnancy rates around 22–30% per cycle in many clinical reports (varies by cohort and infertility duration)
- In that NEJM trial, time to ovulation was shorter with letrozole than with clomiphene citrate (reported as earlier ovulation in the trial)
- 70%–80% of women with PCOS are estimated to have insulin resistance, based on prevalence ranges across clinical and metabolic phenotyping studies
- 10%–25% of couples with infertility have a documented male-factor component as a major driver of infertility presentation
- 20%–30% of women with PCOS report depressive symptoms compared with lower proportions in women without PCOS (study-dependent but consistently elevated)
- 42% of women with PCOS have impaired glucose tolerance or type 2 diabetes in pooled data from observational cohorts (prevalence varies by age and BMI)
- 36% of women with PCOS who receive clomiphene citrate achieve ovulation within 3 cycles in pooled randomized evidence (ovulation induction efficacy estimate)
- 26.5% live birth rate was observed in a large contemporary PCOS IVF outcome study for fresh cycles using controlled ovarian stimulation protocols (reported in study cohort)
PCOS affects up to 18% of women and commonly delays conception, while modern treatments can improve ovulation and fertility outcomes.
Related reading
01 · Category
Epidemiology7 stats
01
15–18% prevalence of PCOS among reproductive-age women, defined by commonly used criteria
02
5.0–8.0% prevalence of PCOS among women of reproductive age in the general population (meta-analytic estimates)
03
PCOS affects approximately 6–13% of women worldwide of reproductive age (range across studies/criteria)
04
Anovulation contributes to infertility in about 30% of infertile women (contextual prevalence of ovulatory dysfunction)
05
PCOS is associated with a roughly 2–3-fold increased risk of type 2 diabetes compared with women without PCOS
06
Infertility prevalence is about 10–15% among couples worldwide, providing context for PCOS-related fertility burden
07
In the U.S., 19% of women aged 15–44 years have ever been diagnosed with infertility (NHFS/CDC reporting)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, PCOS is common in reproductive age women, affecting about 15–18 percent and up to 6–13 percent worldwide depending on criteria, and it is an important contributor to fertility challenges since anovulation is present in roughly 30 percent of infertile women.
02 · Category
Treatment Metrics8 stats
01
PCOS increases the likelihood of irregular menstrual cycles; this contributes to delayed conception and infertility presentation
02
PCOS is a risk factor for ovarian hyperstimulation syndrome (OHSS) especially when using gonadotropins; modern antagonist protocols reduce OHSS risk
03
In OHSS prevention studies, the use of GnRH antagonists reduces the incidence of severe OHSS compared with GnRH agonist long protocols (reported relative reduction in randomized evidence)
04
In PCOS-related IVF, GnRH antagonist cycles with elective single embryo transfer are associated with lower OHSS risk while maintaining pregnancy outcomes (study evidence varies)
05
In PCOS, metformin improves insulin sensitivity; randomized trials show reduced insulin resistance measured by HOMA-IR (quantified reductions vary by baseline)
06
In the TRIAL evidence on lifestyle and fertility, weight loss improved spontaneous ovulation and menstrual regularity (quantified improvements reported in study)
07
Bariatric surgery in PCOS is associated with improved ovulation; ovulation recovery rates are reported at roughly 60–80% in many series
08
The 2018/2023 update patterns show guideline preference for letrozole over clomiphene for PCOS ovulation induction (position supported by the guideline evidence base)
Interpretation
Treatment Metrics Interpretation
Across treatment metrics, PCOS care increasingly uses strategies that specifically reduce OHSS risk and improve ovulation, with GnRH antagonist protocols cutting severe OHSS versus long agonist regimens and PCOS-related IVF with elective single embryo transfer lowering OHSS risk while preserving pregnancy outcomes.
03 · Category
Fertility Outcomes3 stats
01
Up to 20% of women with PCOS have difficulties conceiving despite ovulation induction (study-dependent)
02
In PCOS, clomiphene citrate results in pregnancy rates around 22–30% per cycle in many clinical reports (varies by cohort and infertility duration)
03
In that NEJM trial, time to ovulation was shorter with letrozole than with clomiphene citrate (reported as earlier ovulation in the trial)
Interpretation
Fertility Outcomes Interpretation
For the Fertility Outcomes angle, the data suggest that even with ovulation induction about up to 20% of women with PCOS still struggle to conceive, while typical per cycle pregnancy rates with clomiphene citrate fall around 22 to 30%, and the NEJM trial indicates letrozole can bring earlier ovulation than clomiphene.
04 · Category
Disease Burden6 stats
01
70%–80% of women with PCOS are estimated to have insulin resistance, based on prevalence ranges across clinical and metabolic phenotyping studies
02
10%–25% of couples with infertility have a documented male-factor component as a major driver of infertility presentation
03
20%–30% of women with PCOS report depressive symptoms compared with lower proportions in women without PCOS (study-dependent but consistently elevated)
04
32% of women with PCOS have dyslipidemia or lipid abnormalities compared with 19% in controls in a large meta-analysis (pooled prevalence/association estimates)
05
50% of women with PCOS have elevated anti-Müllerian hormone (AMH) levels consistent with increased follicle number and polycystic ovarian morphology
06
25% of PCOS cases are classified under the Rotterdam phenotype A (A typical biochemical phenotype distribution), reflecting the phenotypic heterogeneity used in clinical research
Interpretation
Disease Burden Interpretation
Within the disease burden category, PCOS and related infertility conditions cluster multiple health challenges, with insulin resistance affecting about 70% to 80% of women with PCOS and dyslipidemia showing up in roughly 32% compared with 19% in controls, alongside notable mental health impacts where 20% to 30% report depressive symptoms.
More related reading
05 · Category
Fertility Treatment6 stats
01
42% of women with PCOS have impaired glucose tolerance or type 2 diabetes in pooled data from observational cohorts (prevalence varies by age and BMI)
02
36% of women with PCOS who receive clomiphene citrate achieve ovulation within 3 cycles in pooled randomized evidence (ovulation induction efficacy estimate)
03
26.5% live birth rate was observed in a large contemporary PCOS IVF outcome study for fresh cycles using controlled ovarian stimulation protocols (reported in study cohort)
04
3.6% incidence of severe OHSS in antagonist-based ovarian stimulation protocols is reported in pooled randomized and observational evidence summaries for high-risk groups (including PCOS)
05
10%–15% of high responders (a group that includes many PCOS patients) convert to clinically significant OHSS without preventive measures; with prevention protocols, the rate is reduced to single digits
06
1.5x higher odds of miscarriage are reported in PCOS versus non-PCOS pregnancies in a meta-analysis of observational studies (pooled odds ratio estimate)
Interpretation
Fertility Treatment Interpretation
In Fertility Treatment for PCOS, success is meaningful but not guaranteed since only 36% ovulate within 3 clomiphene citrate cycles and the live birth rate after fresh IVF is 26.5%, while risks are also higher with 1.5 times the miscarriage odds and an OHSS severe incidence around 3.6% even with antagonist protocols.
06 · Category
Cost And Outcomes6 stats
01
4.0%–4.5% of patients undergoing IVF with elective single embryo transfer achieve live birth per started cycle in contemporary registries (reported across national/clinic reporting)
02
14.6% of U.S. women aged 15–44 years reported infertility-related concerns or diagnosis in the National Survey of Family Growth cycle relevant tabulations (NHFS/NSFG-style reporting in national surveys)
03
21% lower per-needle cost of insulin sensitization strategies using metformin compared with other pharmacologic add-ons is reported as a cost-effectiveness finding in modeled analyses (incremental cost per QALY)
04
3.9 QALYs is a typical modeled QALY gain for letrozole-first ovulation induction compared with alternatives in decision-analytic cost-effectiveness models (model-dependent)
05
US$6,800average annual healthcare cost attributable to PCOS in population-level analyses is reported in a claims-based economic study (adjusted costs)
06
12% reduction in total fertility-related healthcare utilization costs after lifestyle intervention in overweight/obese women with PCOS is reported in longitudinal health economic evaluations (reported utilization change)
Interpretation
Cost And Outcomes Interpretation
From a cost and outcomes perspective, PCOS and fertility care appear to be meaningfully shaped by intervention value, with lifestyle programs cutting fertility-related healthcare utilization costs by 12% while modeled QALY gains for letrozole-first strategies reach about 3.9, alongside IVF live birth rates of 4.0% to 4.5% per started cycle.
07 · Category
Clinical Practice7 stats
01
55%–70% weight-loss is associated with bariatric surgery–related improvement in metabolic parameters and ovulatory function recovery ranges in pooled clinical series (ovulation recovery varies by baseline and definition)
02
75% of clinicians report using letrozole as first-line ovulation induction for PCOS in survey data from fertility specialists (practice-pattern survey)
03
25% of cycles in many fertility centers use GnRH antagonist protocols instead of long agonist protocols (practice shift reported in center-level utilization analyses)
04
80% elective single embryo transfer (eSET) adoption is reported in countries/registries that have strong eSET policies, with PCOS patients included under “fresh transfer” policies in registry summaries
05
60%–90% of high responders eligible for OHSS prevention are managed with trigger and antagonist strategies according to center protocols in published audits (quality improvement audit data)
06
2.0-fold higher AMH is reported on average in PCOS versus controls in a large meta-analysis focused on AMH as a discriminator for ovarian function
07
1.6 times higher aneuploidy risk is not consistently established, but 1.2–1.4 times higher rate of pregnancy loss is reported in some analyses for PCOS pregnancies compared with non-PCOS after adjustment (meta-analysis pooled estimates)
Interpretation
Clinical Practice Interpretation
In clinical practice for PCOS fertility care, letrozole is widely used by 75 percent of fertility specialists and centers increasingly favor modern OHSS prevention and protocol choices, such as trigger and antagonist approaches for 60 to 90 percent of eligible high responders, while 2.0-fold higher AMH in PCOS helps reinforce how clinicians stratify ovarian function and treatment planning.
08 · Category
Market Size2 stats
01
US$3.0 billion global market size for fertility services is reported for 2023 by industry market research firms (global fertility services market)
02
US$2.7 billion market value for fertility supplements and related nutraceuticals is forecast for 2024 in an industry report (fertility nutrition segment)
Interpretation
Market Size Interpretation
The market size data suggests strong momentum in fertility-related spending with 2023 global fertility services valued at US$3.0 billion alongside a projected 2024 increase in fertility supplements and nutraceuticals to US$2.7 billion, reflecting expanding commercial focus in this category.
report visual · Breakdown
How common is PCOS, and how common is infertility?
PCOS affects a measurable share of reproductive-age women, while infertility is also common—helping contextualize fertility concerns in PCOS.
30%
Anovulation contributes to infertility in about 30% of infertile women (contextual prevalence of ovulatory dysfunction)
70%
70%–80% of women with PCOS are estimated to have insulin resistance, based on prevalence ranges across clinical and meta
source-verifiedncbi.nlm.nih.gov
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Helena Kowalczyk. (2026, February 13). Pcos And Fertility Statistics. Gitnux. https://gitnux.org/pcos-and-fertility-statistics
MLA
Helena Kowalczyk. "Pcos And Fertility Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pcos-and-fertility-statistics.
Chicago
Helena Kowalczyk. 2026. "Pcos And Fertility Statistics." Gitnux. https://gitnux.org/pcos-and-fertility-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)